$599

Madrigal, Pfizer, and Amgen Q3 ’26 Earnings; MiniMed Appoints CMO

A series of cardiometabolic-related news items has been observed from Madrigal, Pfizer, MiniMed, and Amgen. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here